Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
DRG anticipates the next ten years to be an exciting time in the hemophilia A space as the number of treatment options grow for patients with, and without, inhibitors. The hemophilia A pipeline is diverse, both in terms of technology type and administration route, and we are witnessing a shift in R&D emphasis; there is growing interest in nonfactor treatment approaches to restore coagulation. Examples include the launch of Roche/Chugai’s bispecific antibody Hemlibra, and the development of gene therapies, such as BioMarin’s BMN 270, and the anti-TFPI drug class, with agents like Novo Nordisk’s concizumab. Despite novel nonfactor hemophilia agents forecast to launch, DRG expects the high demand for factor concentrates to persist. We anticipate the factor concentrate market will remain highly competitive, and pipeline agents are looking to further evolve this treatment approach.
Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
United States, EU5, Japan
PRIMARY RESEARCH INFO
20 country-specific interviews with thought-leading hematologists, specializing in hemophilia. Supported by survey data collected for this and other DRG research.
Alnylam, Bayer, BioMarin, Bioverativ, Chugai, CSL Behring, Novo Nordisk, Octapharma, OPKO, Pfizer, Roche, Sanofi, Shire, Spark
Advate, Adynovate/Adynovi, Afstyla, BMN 270, concizumab, Eloctate/Elocta, FEIBA, fitusiran, FVIIa marzeptacog, Helixate, Hemlibra, Kogenate, Kovaltry, N8-GP, Novoeight, NovoSeven, Nuwiq, OPK88005, ReFacto/Xyntha, SPK-8011
Already a Client? Log in to access this report.
Kerri Brown, is an analyst with Decision Resources Group, focused on finding stories in data and developing products to inform strategic decisions in the hemophilia and diabetes spaces. Kerri holds a master of pharmacy degree from King’s College London with 1 st class honors. Prior to joining DRG, she was a national clinical educator at a UK diabetes start-up, and has extensive experience of diabetes medical devices. Kerri has worked at AstraZeneca, and as a pharmacist in a national psychiatric clinical trial center. In addition to her work at DRG, Kerri is a practicing pharmacist with extensive clinical experience of UK physician prescribing in diabetes.
Abey John is a medical graduate with a Master’s in Public Health and has been associated with DRG since September 2015. He works with a global team of epidemiologists in performing systematic reviews of assigned diseases and prepare forecast models for clients. He also is involved in producing analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets and have an overall experience of three years working in different healthcare sectors across the country. Prior to joining DRG, Abey had been working with Jhpiego (an affiliate of Johns Hopkins Medical University) in implementing Family Planning Health Programs in India with collaborating with the Government of India. He also has worked with a grassroots level NGO as a health team manager which worked for the benefit of the rural population living in the foothills of the Himalayas.